October, 2021

article thumbnail

Generic Portfolio Management, Partnering with Brands, and Staying Competitive

Drug Patent Watch

This is my talk from the 14th Annual Portfolio Planning and Partnership for Generic Conference. I discuss: Identifying generic entry opportunities at the earliest stages Discovering opportunities that avoid litigation…. The post Generic Portfolio Management, Partnering with Brands, and Staying Competitive appeared first on DrugPatentWatch - Make Better Decisions.

144
144
article thumbnail

Sphere Fluidics closes a $40 million funding round led by Sofinnova Partners and Redmile Group

Drug Discovery Today

Cambridge, UK, 28 October 2021: Sphere Fluidics, a company that has developed and is commercialising single cell analysis systems underpinned by its proprietary picodroplet technology, announced today that it has closed a $40 million (circa £30 million) investment round. The round was led by Sofinnova Partners (Paris, France) and Redmile Group (San Francisco, USA) co-investing on equal terms.

113
113
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Conducting Patient Access in an Evolving Market

Drug Channels

Today’s guest post comes from Bill Dupere, Practice Lead and VP of Market Access Solutions and Eric Willis, VP of Operations Hub and Reimbursement Services at TrialCard. Bill and Eric discuss the complexities of digital patient support program technologies and introduce TrialCard’s integrated suite of solutions. To learn more, please contact Trialcard at sales@trialcard.com or visit them in booth #416 at the upcoming Asembia Specialty Pharmacy Summit from October 26 to 29, 2021.

article thumbnail

U.S. Food and Drug Administration Approves VUITY™ (pilocarpine HCI ophthalmic solution) 1.25%, the First and.

The Pharma Data

– Presbyopia, or age-related blurry near vision, is a common, progressive condition that reduces the eye’s ability to focus on near objects, affecting most adults over the age 40 – Phase 3 clinical studies demonstrated VUITY works in as early as 15 minutes and lasts for up to 6 hours, as measured on day 30, to improve near and intermediate vision without impacting distance vision – Allergan, an AbbVie company, continues legacy of eye care innovation with VUITY, a first-of

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Biomarker Discovery and Validation Using a Combination of In Vitro and In Vivo Studies

Crown Bioscience

In this post we explore how using a range of translational preclinical models can be used to accelerate the discovery and validation of predictive biomarkers, with the goal of de-risking drug development to increase the likelihood of clinical success for therapeutic candidates.

article thumbnail

Exploratory Data Analysis With mols2grid and Bemis-Murcko Frameworks

Practical Cheminformatics

One of the most common tasks in Cheminformatics is exploratory data analysis (EDA). Given a new dataset, we often need to rapidly explore the chemistry in a set containing hundreds, or even thousands, of molecules. One useful technique for EDA is the Bemis-Murcko framework. This technique, originally published by Guy Bemis and Mark Murcko, provides a simple but elegant means of grouping molecules.

52

More Trending

article thumbnail

ioSkeletal Myocytes; the first supply of consistent, scalable, human muscle cells provide transformative new models for research and drug discovery

Drug Discovery Today

Highly consistent and scalable supply of lab grown human skeletal muscle cells provide an effective and biologically relevant tool for research and drug development in conditions as diverse as metabolic and muscle diseases and ageing.

Research 100
article thumbnail

Follow the Vial: The Buy-and-Bill System for Distributing and Reimbursing Provider-Administered Outpatient Drugs

Drug Channels

By reader request, we present below a channel flow chart illustrating the buy-and-bill process for provider-administered drugs. This chart complements Follow the Dollar: The U.S. Pharmacy Distribution and Reimbursement System for Patient-Administered, Outpatient Brand-name Drugs. To further help you understand this channel, I have also included a brief video to explain the buy-and-bill system.

article thumbnail

FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic.

The Pharma Data

Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor (TKI) treatments 1 In the pivotal Phase III ASCEMBL trial, Scemblix demonstrated significant and clinically meaningful superiority in major molecular response (MMR) rate vs.

article thumbnail

5 Surprising Benefits of Joining a Clinical Trial

Olympian Clinical Research

If you’re thinking about joining a clinical trial, there are many benefits you could look forward to. It’s not just the potential for medical breakthroughs that has people excited – it’s also the feeling of being part of something important and potentially life-changing. But how can you tell if clinical trials are right for you? We’ve outlined five reasons why joining a clinical trial might be in your best interest.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Webinar: using an API to access ChEMBL

The ChEMBL-og

If you use ChEMBL via the interface and are interested in programmatic approaches then join our webinar on November 10th @ 15:30 to find out more ! In this webinar, we'll provide an overview of the ChEMBL and UniChem APIs and work through some common examples. In the meantime, don’t forget that we have further documentation on our web services as well as a recent ChEMBL webinar, a Blog and series of FAQs.

52
article thumbnail

Ointment dosed drug patent expirations by year

Drug Patent Watch

This chart shows the patent expirations for ointment dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Ointment dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

Milestone moment for the region’s life science sector as construction on No. 1 Birmingham Health Innovation Campus gets underway.

Drug Discovery Today

Construction of No.1 Birmingham Health Innovation Campus (BHIC) in Selly Oak is underway, marking a major milestone for the region’s rapidly growing life sciences sector.

Science 100
article thumbnail

White Bagging Update: PBMs’ Specialty Pharmacies Keep Gaining on Buy-and-Bill Oncology Channels

Drug Channels

Payers have long sought to disrupt the buy-and-bill channel. Coming out of the pandemic (maybe?), specialty pharmacies—via white, brown, and clear bagging—continue to displace buy-and-bill distribution channels for provider-administered oncology drugs. Check out the latest 2021 data below. The battle for the specialty patient pits hospitals against insurers—and their respective specialty pharmacies.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Lower talk, further action New report patronized by ViiV Healthcare provides roadmap to achieve health equity by 2040

The Pharma Data

Lower talk, further action New report patronized by ViiV Healthcare provides roadmap to achieve health equity by 2040. ViiV Healthcare blazoned the release of Achieving health equity a roadmap to barring difference, a new report conducted by Economist Impact, a division of The Economist Group, that explores the openings that could be created by barring health difference in the UK and US over the coming 20 times, while charting a bold course for unified action.

article thumbnail

Accelerating Drug Discovery and Development with Flow Cytometry

Crown Bioscience

In this post, we discuss modern flow cytometry as a game-changer for cell functional assays, immune monitoring, and function-based screening of drug candidates to support and accelerate your biomarker strategy and translational programs.

Drugs 52
article thumbnail

Command and Control the Life Science R&D Lab - Webinar Recap

The Strateos Blog: Drug Discovery

Strateos was pleased to sponsor a webinar on Sept 27, 2021 to discuss how a single unified cloud-based software platform can overcome current operational inefficiencies in life science R&D labs. Alok Gupta, SVP of Engineering, Venkat (VK) Eswarakrishanan, Product Manager, and Vanessa Biggers, Director of Engineering, Scientific Technologies at Strateos led the discussion.

Science 52
article thumbnail

New patent for Hq Spclt drug CALCIUM GLUCONATE IN SODIUM CHLORIDE

Drug Patent Watch

Annual Drug Patent Expirations for CALCIUM+GLUCONATE+IN+SODIUM+CHLORIDE Calcium Gluconate In Sodium Chloride is a drug marketed by Fresenius Kabi Usa and Hq Spclt Pharma and is included in two NDAs. It…. The post New patent for Hq Spclt drug CALCIUM GLUCONATE IN SODIUM CHLORIDE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 98
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Pharmaceutical System Thinking and Digital Infrastructure: Seeking Inspiration in Human Cognition

The Connected Lab

Exploring how digital transformation will revolutionize process optimization and decision-making within the pharmaceutical industry Digital transformation is ushering in a new era for pharmaceutical research and manufacturing, characterized by advanced solutions, such as automation, networked technologies and machine learning, that support faster decision-making and more efficient process control.

article thumbnail

Fresh Evidence: How Health Systems Steer Prescriptions to Their Own Specialty Pharmacies

Drug Channels

Hospitals and health systems are rapidly expanding their internal specialty pharmacies—and they’re using questionable tactics to boost revenues and profits. A new American Society of Hospital Pharmacists (ASHP) survey of health system pharmacies offers fresh insights into how these systems steer prescriptions to their internal specialty pharmacies: For most health systems' in-house specialty pharmacies, more than 90% of specialty prescriptions are written by system-employed physicians.

article thumbnail

ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be enforced successfully in a variety of European healthcare settings

The Pharma Data

ViiV Healthcare presents positive interim data showing Vocabria (cabotegravir) and Rekambys (rilpivirine) can be enforced successfully in a variety of European healthcare settings. ViiV Healthcare, the global specialist HIV company maturity possessed by GlaxoSmithKline plc (“ GSK”), with PfizerInc. and Shionogi Limited as shareholders, moment presented positive interim data from the CARISEL (Cabotegravir and Rilpivirine Perpetration Study in European Locales) study, which was initiated and condu

article thumbnail

How to Detect, Characterize, and Evaluate CAR-Ts: Top 13 Questions

Crown Bioscience

Review key questions on preclinical models and rare cell analysis technology for assessing CAR-T cell therapies from our recent webinar , answered by Dr. Rajendra Kumari, Global Head of Scientific Communication.

article thumbnail

AI Model Predicts Drug Synergies for Fighting COVID-19

Nvidia Developer: Drug Discovery

A new study out of the Massachusetts Institute of Technology (MIT) could arm healthcare workers with the information needed to effectively treat COVID-19. A new study out of the Massachusetts Institute of Technology (MIT) could arm healthcare workers with the information needed to effectively treat COVID-19 patients. Recently published in the Proceedings of the National Academy of Sciences , the research develops a deep learning model that determines the best drug combinations for fighting the v

Drugs 52
article thumbnail

Which pharmaceutical drugs have the most drug patents in Mexico?

Drug Patent Watch

This chart shows the drugs with the most patents in Mexico. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Mexico? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Help us prioritise!

The ChEMBL-og

Over the years we've added many new features to ChEMBL and some of these have proved to be particularly valuable to our users. However, our resources are finite, and in order to continue to bring you exciting new improvements, we may sometimes need to re-evalutate features that are not well used and/or costly to maintain. To get the clearest possible view of which of our current data types, formats and access mechanisms are most important to you, we've put together a brief survey.

52
article thumbnail

Supporting Patient Adherence Through Electronic Prior Authorization and First Fill Copay Programs

Drug Channels

Today’s guest post comes from David Fidler, Senior Director of Product Innovation at ConnectiveRx. David discusses how electronic prior authorization (ePA) and first-fill, buy-down programs can boost patient adherence to specialty therapies. On November 3rd at 1:00 pm ET, ConnectiveRx will host First Fill, No Wait: How to Make it Happen , a free webinar about copay ePA.

article thumbnail

Bayer to present new data from comprehensive finerenone clinical trial program

The Pharma Data

New analysis from the Phase III FIGARO-DKD study will be presented, which investigated the impact of finerenone on renal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) / A subgroup analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, will be presented, which investigated the impact of finerenone on renal outcomes on top of standard of care / Additional finerenone data from the FIDELIO-DKD study and the pooled analysis FIDELITY wi

article thumbnail

Next Generation Syngeneic Models: Top 14 Questions

Crown Bioscience

Dr Davy Ouyang, CrownBio Vice President of Scientific Research & Innovation answers the most popular questions from his recent syngeneic model webinar , covering the latest research, model developments , and platforms for moving past syngeneics for advanced immuno-oncology studies.

article thumbnail

Latest news on drug repurposing in oncology #11

The Anticancer Fund

22 October 2021 Language EN Drug repurposing is a strategy for identifying new uses for approved drugs, outside the scope of the original indication. It is one of the focus areas of the Anticancer Fund. Below, we have listed recent findings about the repurposing of generic drugs in oncology. Our intention is to help bring these findings to the attention of the broader cancer research community.

Drugs 40
article thumbnail

Which pharmaceutical companies have the most solution dosed drugs?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most solution dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most solution dosed drugs…. The post Which pharmaceutical companies have the most solution dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Pomegranate Peel Extract Shows Promising Antiviral Effects Against COVID-19

PerkinElmer

Since the World Health Organization (WHO) declared the novel coronavirus (COVID-19) outbreak a global pandemic on March 11, 2020, researchers around the world have been working tirelessly to discover effective preventive treatments and therapeutic agents. Currently, the FDA has only approved one drug, Veklury (remdesivir), for treatment of COVID-19.

Virus 52
article thumbnail

Machine Learning, AI, and Platform Technology: Drug Discount Management’s Big Leap Forward

Drug Channels

Today’s guest post comes from Scott Johnsen, VP of Product at Kalderos. Scott discusses the advantages of using artificial intelligence and machine learning to efficiently process reimbursement data and avoid duplicates. Learn more about Kalderos’ solutions to solve drug discount management challenges at scale during a free webinar on November 17: The Power of the Platform: How a Trusted Network Delivers Outcomes That Are a Win for All.

Drugs 66
article thumbnail

Takeda Announces Acquisition of Own Shares

The Pharma Data

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) announced that its Board of Directors resolved today to engage in the acquisition of its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, as detailed below. “At our current share price, we see an opportunity to buy back our shares at a substantial discount to what we perceive is their underlying value,” said Costa Saroukos, directo